Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 93.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $17.839 million which missed the analyst consensus estimate of $18.366 million by 2.87 percent. This is a 18.86 percent increase over sales of $15.009 million the same period last year.